NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 341 filers reported holding NEKTAR THERAPEUTICS in Q2 2019. The put-call ratio across all filers is 2.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $2,089,000 | -21.7% | 154,647 | +4.1% | 0.00% | -33.3% |
Q3 2021 | $2,669,000 | +15.9% | 148,622 | +10.7% | 0.00% | 0.0% |
Q2 2021 | $2,303,000 | -21.2% | 134,224 | -8.2% | 0.00% | -25.0% |
Q1 2021 | $2,924,000 | +12.9% | 146,216 | -4.0% | 0.00% | 0.0% |
Q4 2020 | $2,590,000 | +6.2% | 152,372 | +3.7% | 0.00% | -50.0% |
Q3 2020 | $2,438,000 | -32.5% | 146,964 | -5.8% | 0.01% | -52.9% |
Q2 2020 | $3,612,000 | +64.3% | 155,965 | +26.7% | 0.02% | -5.6% |
Q1 2020 | $2,198,000 | -67.7% | 123,124 | -61.0% | 0.02% | -60.9% |
Q4 2019 | $6,815,000 | +34.4% | 315,728 | +13.5% | 0.05% | +12.2% |
Q3 2019 | $5,069,000 | +138.8% | 278,287 | +366.3% | 0.04% | +115.8% |
Q2 2019 | $2,123,000 | +62.6% | 59,674 | +53.6% | 0.02% | +26.7% |
Q1 2019 | $1,306,000 | -44.3% | 38,860 | -45.5% | 0.02% | -25.0% |
Q4 2018 | $2,343,000 | -69.0% | 71,295 | -42.5% | 0.02% | -66.7% |
Q3 2018 | $7,561,000 | -36.1% | 124,026 | -48.8% | 0.06% | -40.6% |
Q2 2018 | $11,826,000 | -20.1% | 242,186 | +73.9% | 0.10% | -32.2% |
Q1 2018 | $14,795,000 | +119.5% | 139,236 | +23.4% | 0.15% | +217.0% |
Q4 2017 | $6,739,000 | +978.2% | 112,843 | +333.5% | 0.05% | +683.3% |
Q3 2017 | $625,000 | -42.3% | 26,032 | -53.0% | 0.01% | -45.5% |
Q2 2017 | $1,083,000 | +23.9% | 55,407 | +48.7% | 0.01% | +10.0% |
Q1 2017 | $874,000 | +34.5% | 37,253 | -29.7% | 0.01% | +66.7% |
Q4 2016 | $650,000 | +550.0% | 52,999 | +808.1% | 0.01% | +500.0% |
Q3 2016 | $100,000 | +88.7% | 5,836 | +58.1% | 0.00% | 0.0% |
Q2 2016 | $53,000 | -51.8% | 3,692 | -63.3% | 0.00% | -50.0% |
Q3 2015 | $110,000 | -74.4% | 10,065 | -74.2% | 0.00% | -71.4% |
Q1 2015 | $430,000 | -19.6% | 39,069 | +13.1% | 0.01% | -12.5% |
Q4 2014 | $535,000 | +249.7% | 34,544 | +173.0% | 0.01% | +300.0% |
Q3 2014 | $153,000 | -83.2% | 12,654 | -82.2% | 0.00% | -85.7% |
Q2 2014 | $910,000 | +3691.7% | 70,980 | +3560.6% | 0.01% | – |
Q1 2014 | $24,000 | -82.2% | 1,939 | -83.7% | 0.00% | -100.0% |
Q4 2013 | $135,000 | -86.4% | 11,868 | -87.5% | 0.00% | -89.5% |
Q3 2013 | $991,000 | +319.9% | 94,850 | +364.2% | 0.02% | +216.7% |
Q2 2013 | $236,000 | – | 20,435 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |